The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch
HighlightsOrder placed for 20,000 units of the Company's needle-free Thymosin Alpha-1 transdermal patch in preparation for commercial releaseTA1 is a naturally occurring peptide studied for its immune-modulating properties, historically delivered by injection¹The Company believes it could be among the first to market with a Thymosin Alpha-1 transdermal patch.Second product to move from the Company's transdermal development pipeline into commercial productionEach patch is formulated to deliver 2...